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Background: Pediatric pituitary adenomas are rare, accounting for <3 % of all childhood intracranial tumors, the
majority of which are prolactinomas. Consequently, they are often misdiagnosed as other suprasellar masses such
as craniopharyngiomas in this age group. Whilst guidelines exist for the treatment of adult prolactinomas, the
management of childhood presentations of these benign tumors is less clear, particularly when dopamine agonist
therapy fails. Given their rarity, childhood-onset pituitary adenomas are more likely to be associated with a variety
of genetic syndromes, the commonest being multiple endocrine neoplasia type 1 (MEN-1).
Case description: We present a case of an early-onset, treatment-resistant giant prolactinoma occurring in an
11-year-old peripubertal boy that was initially sensitive, but subsequently highly resistant to dopamine agonist
therapy, ultimately requiring multiple surgical debulking procedures and proton beam irradiation. Our patient is
now left with long-term tumor- and treatment-related neuroendocrine morbidities including blindness and
panhypopituitarism. Only after multiple consultations and clinical data gained from 20-year-old medical records was
a complex, intergenerationally consanguineous family history revealed, compatible with MEN-1, with a splice site
mutation (c.784-9G > A) being eventually identified in intron 4 of the MEN1 gene, potentially explaining the
difficulties in management of this tumor. Genetic counseling and screening has now been offered to the
wider family.
Conclusions: This case emphasizes the need to consider pituitary adenomas in the differential diagnosis of all
pediatric suprasellar tumors by careful endocrine assessment and measurement of at least a serum prolactin
concentration. It also highlights the lack of evidence for the optimal management of pediatric drug-resistant
prolactinomas. Finally, the case we describe demonstrates the importance of a detailed family history and the role
of genetic testing for MEN1 and AIP mutations in all cases of pediatric pituitary adenoma.
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Pituitary adenomas account for <3 % of all childhood
intracranial tumors with an estimated incidence of 0.1
cases/million/year [1, 2]. Prolactin (PRL)-secreting tumors
alone account for 50-70 % of pituitary adenomas in children
<20 years of age [3–5]. These are further classified into
microprolactinomas (≤1 cm in maximum dimensions),
macroprolactinomas (>1 cm) and giant prolactinomas
(>4 cm with a serum PRL of >5300-10600 mU/l) [6, 7].
First-line therapy consists of dopamine agonists such as
cabergoline, with surgery and radiotherapy being reserved
for drug-resistant tumors or neuro-ophthalmological emer-
gencies. Whilst 20-30 % of patients with known multiple
endocrine neoplasia type 1 (MEN-1) develop prolactinomas
[4, 8, 9], up to 6.5 % of sporadic pediatric prolactinomas are
associated with previously undiagnosed MEN-1 [10].
We report a patient presenting to our quaternary
pediatric neuroendocrine and oncology units with a
treatment-resistant giant prolactinoma. His complex
genetic history and challenging management illustrates
the necessity for thorough history-taking, specialistFig. 1 Patient family tree. Our patient’s family tree a at initial consultation a
and asymptomatic relatives who were subsequently confirmed to carry themultidisciplinary management and the potential for
long-term neuroendocrine morbidity in this rare tumor.
Case presentation
An 11-year-old Middle Eastern boy was referred to Great
Ormond Street Hospital for Children with four years of
headaches and 18 months of visual deterioration, previ-
ously investigated with a reportedly normal brain CT scan
in his country of origin. There was no galactorrhea. At
presentation he had a right-sided relative afferent pupillary
defect, optic atrophy and could only perceive light with
his right eye and count fingers with his left eye. Auxology
was normal and he was in early puberty with testicular
volumes of 4 mls bilaterally. Initial family history revealed
an inter-generational multiply consanguineous family
(Fig. 1a), with one maternal first half-cousin once removed
treated with cabergoline at age 18 years and one paternal
first half-cousin once removed undergoing transsphenoi-
dal surgery at age 45 years, both for macroprolactinomas.
Magnetic resonance imaging revealed a large, avidly-
enhancing heterogeneous sellar and suprasellar massnd b at last follow-up after discovery of several other symptomatic
same c.784-9G > A MEN1 mutation as our proband
Fig. 2 Patient MRI images and biochemistry results. Serial T1-weighted MRI images with gadolinium contrast demonstrating appearances of our
patient’s giant prolactinoma a-b at diagnosis, c-d at first progression, e-f after first debulking, g-h at second progression, i-j after second
debulking and radiotherapy, k-l at last follow-up. Arrows indicate tumor mass whilst arrowheads indicate sites of progression. m Serial prolactin
concentrations (black line) and corresponding cabergoline dose (gray shaded area) in our patient since diagnosis illustrating multiple biochemical
relapses despite multimodality treatment
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chiasm and encasing both internal carotid arteries with a
maximal transverse diameter of 5.5 cm (Fig. 2a-b). A
provisional radiological diagnosis of craniopharyngioma
was made with a plan for surgical resection. However,
biochemical testing revealed marked hyperprolactinemia
(PRL 23723 mU/l, normal range 55-318) leading to the
revised diagnosis of a giant prolactinoma. Dynamic test-
ing revealed deficiencies in growth hormone (GH, peak
to glucagon stimulation 1.1 ng/ml; insulin-like growth
factor-1 (IGF-1) 196 ng/ml, normal range 143-693) andthyroid-stimulating hormone (TSH 3.7 mU/l, normal
range <6.0; free thyroxine (fT4) 10.3 pmol/l, normal
range 10.8-19.0) but normal hypothalamo-pituitary-
adrenal (peak cortisol 516 nmol/l to synacthen stimulation)
and -gonadal function (luteinizing hormone 0.3 U/l, follicle-
stimulating hormone 0.9 U/l, testosterone 1.68 nmol/l).
Our patient was commenced on 250 μg/week cabergo-
line and levothyroxine supplementation. Despite an ini-
tial excellent PRL reduction in response to therapy, his
tumor became extremely drug-resistant despite cabergoline
dose escalation to 3.5 mg/week (Fig. 2m). Multiple relapses
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spheric debulking procedures and adjuvant proton beam
irradiation, with the second debulking and radiotherapy
undertaken at the Children’s Hospital of Philadelphia
(CHOP, Fig. 2c-l). Tumor histology confirmed a prolac-
tinoma with a high Ki67 index (11 %). During the sec-
ond surgical debulking he experienced a preoperative
anesthesia-related hemorrhagic stroke causing a transient
left hemiparesis, and post-operatively lost all residual vi-
sion. He now has panhypopituitarism but has demon-
strated declining PRL concentrations (500 mU/l) whilst
maintained on 5 mg/week of cabergoline.
His complex family history alerted clinicians to the
likelihood of an underlying genetic diagnosis but despite
repeated consultations with multiple specialists (HAS,
MK, OJ) no common ancestor linking all three macro-
prolactinoma cases could be found. Genetic testing of
our patient for both MEN1 and AIP mutations revealed
a heterozygous MEN1 intronic splice site mutation
(c.784-9G > A). This has previously been shown to result
in alternative splicing, a premature stop codon and a
truncated, inactive MENIN protein [11–13].
Subsequent questioning revealed a history of renal
stones and primary hyperparathyroidism in our patient’s
mother and two maternal aunts, as well as a history con-
sistent with MEN-1 (macroprolactinoma, primary hyper-
parathyroidism and gastrinoma) in his deceased maternal
grandmother (Fig. 1b) who had been managed by our
adult colleagues in the United Kingdom two decades earl-
ier. Genetic testing confirmed the same mutation in his
sister, mother, maternal grandmother, one maternal aunt
and her two children, but not in his father or his paternal
uncle. Most recently, our patient has developed primary
hyperparathyroidism, and a parathyroidectomy is being
planned. He continues to undergo regular screening in-
cluding gut hormone profiling and echocardiograms at
CHOP, all of which have been normal thus far. We are in
the process of collaboratively tracing and screening other
asymptomatic relatives in the wider family at risk.
Discussion
The rarity of pediatric pituitary adenomas means that they
are often not considered in the differential diagnosis of
suprasellar tumors in this age group, leading to the poten-
tial misdiagnoses of craniopharyngioma or low-grade gli-
oma, for which primary treatments are predominantly
surgical, chemotherapeutic and/ or radiotherapeutic in na-
ture. This case highlights the importance of a routine
endocrine evaluation in all such cases, not only to docu-
ment potential tumor-related pituitary dysfunction but
also to identify functioning pituitary adenomas by measur-
ing serum PRL, GH and adrenocorticotropic hormone,
particularly as non-functioning pituitary adenomas are
rare in children [14, 15, 5]. It also emphasizes thatmacroprolactinomas often present with non-endocrine
raised intracranial pressure symptoms particularly in pre-
pubertal males [16–19, 15]. It is important to distinguish
true prolactinomas from hyperprolactinemia from other
causes, but concentrations >5300 mU/l are usually diag-
nostic [7]. In all suspected cases, screening for macropro-
lactinemia [20], as well as serial serum dilution to exclude
the hook effect – where extreme hyperprolactinemia
causes falsely low assay results through interference of
antibody-antigen complex formation [6, 21] – should al-
ways be performed.
Medical monotherapy with dopamine agonists is rec-
ommended as first-line treatment for all prolactinomas
due to their excellent efficacy, likely preservation of
residual pituitary function and low side-effect profile
[7, 22]. Cabergoline in particular has an established rec-
ord of being better-tolerated than bromocriptine with
higher rates of resolution [7]. Cardiac valve regurgitation
with high cumulative doses (4000 mg) has been de-
scribed in Parkinson syndrome patients [23], but this is
usually not reached with prolactinomas, as demonstrated
by several adult studies [7, 24–27]. However, young pa-
tients such as ours commencing treatment earlier in life
are more likely to reach this critical threshold, and at the
current dose of 5 mg/week our patient will be exposed to
4000 mg of cabergoline within 16 years post-diagnosis, un-
less doses can be reduced in response to the efficacy of
radiotherapy. Dose-safety profiles have additionally not
been established in children, in whom toxicity even at
moderate cabergoline doses may be increased. Quinago-
lide, a more recent non-ergot derived dopamine agonist is
purported to have fewer side effects but to our knowledge
has not been used in children [28].
The mechanism for development of drug-resistance is
not well understood, and is thought to relate to dopamine
D2 receptor downregulation [7]. MEN-1 is associated with
larger tumors (84 % vs. 24 %) and treatment-resistance
(56 % vs. 10 %) [29, 9]. Second-line management options
for drug-resistant adult tumors include maximizing caber-
goline dose to 11 mg/week, transsphenoidal or transcra-
nial surgical resection, radiotherapy and the alkylating
agent temozolomide [7, 6, 30, 31]. However, knowledge of
the maximum safe therapeutic cabergoline dose, speed of
dose escalation, long-term toxicities of temozolomide, and
experience in pediatric transsphenoidal resections is lim-
ited. Consequently, optimal management of pediatric pitu-
itary adenomas remains unclarified, suggesting the need
for treatment in specialist neuroendocrine units with both
adult and pediatric experience. Several authors report
long-term tumor- and/ or treatment-related morbidities
including hypopituitarism, obesity, dyslipidemia, infertility
and reduced bone mineral density [16–18, 32, 6, 3].
9-22 % of pediatric pituitary adenomas are associated
with genetic tumor-predisposing syndromes, the most
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lence of 0.02-0.2 per 1000 [10, 29]. Whilst primary hyper-
parathyroidism is the commonest presenting manifestation,
17 % will present with a pituitary adenoma (classically a
prolactinoma) [9]. As illustrated here, MEN-1 is an auto-
somal dominant condition characterized additionally by
enteropancreatic tumors, non-functioning adrenocortical
adenomas, angiofibromas, collagenomas, thyroid aden-
omas, meningiomas and other neuroendocrine tumors [8].
Other genetic endocrine syndromes associated with pi-
tuitary tumors are the familial isolated pituitary adenoma
(FIPA) syndrome (of which AIP mutations are a subset),
multiple endocrine neoplasia type 4 (CDKN1B), Carney
complex (PRKAR1A), McCune-Albright syndrome (GNAS),
SDH-related pituitary adenoma syndrome (SDHB, SDHC,
SDHD), neurofibromatosis type 1 (NF1) and DICER1 syn-
drome [33, 34, 4, 35–37].
Several authors strongly suggest testing for both MEN1
and AIP germline mutations in all pediatric patients with
PRL- and GH-secreting pituitary adenomas as they may
be index cases for a given family [10, 33, 29]. A useful al-
gorithm has been proposed by Korbonits et al. (2012).
This is particularly important given that current guidelines
recommend testing first-degree relatives of index cases
and performing annual biochemical screening in carriers
for insulinomas, PRL- and GH-secreting pituitary aden-
omas from age 5 years and for hyperparathyroidism from
age 8 years [8].
Conclusion
Pituitary adenomas must be considered in the differential
diagnosis of all pediatric suprasellar masses, therefore
mandating a detailed endocrine review and an accurate
serum PRL measurement as management differs markedly
from that of other tumors. Optimal management of do-
pamine agonist-resistant tumors in childhood remains
unclear. A detailed family history of brain tumors and
MEN-1-associated symptoms such as renal stones must
be obtained and may require several consultations before
being fully elucidated. We recommend that all children
with PRL- or GH-secreting pituitary adenomas undergo
MEN1 and AIP mutation testing, with subsequent screen-
ing of first-degree relatives if found positive.
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